Vfend

In the US, Vfend (voriconazole systemic) is a member of the drug class azole antifungals and is used to treat Aspergillosis - Invasive, Blastomycosis, Candida Infections - Systemic, Coccidioidomycosis - Meningitis, Cutaneous Fungal Infection, Esophageal Candidiasis, Eumycetoma, Fungal Infection - Internal and Disseminated, Fungal Meningitis, Fungal Pneumonia, Fusariosis, Ocular Fungal Infection, Pseudoallescheriosis and Systemic Fungal Infection.

US matches:

• Vfend


• Vfend Suspension


• Vfend Tablets


• Vfend I.V.


• Vfend Oral

UK matches:

• VFEND 50 mg and 200 mg film-coated tablets, VFEND 200 mg powder for solution for infusion,VFEND 40 mg/ml powder for oral suspension (SPC)

Ingredient matches for Vfend

Voriconazole

Voriconazole is reported as an ingredient of Vfend in the following countries:

• Argentina


• Australia


• Austria


• Belgium


• Belize


• Brazil


• Canada


• Chile


• China


• Colombia


• Costa Rica


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• El Salvador


• Finland


• France


• Georgia


• Germany


• Guatemala


• Honduras


• Hong Kong


• Hungary


• Iceland


• India


• Indonesia


• Ireland


• Israel


• Italy


• Japan


• Luxembourg


• Malaysia


• Mexico


• Netherlands


• New Zealand


• Nicaragua


• Norway


• Panama


• Peru


• Poland


• Portugal


• Romania


• Russian Federation


• Serbia


• Singapore


• Slovakia


• Slovenia


• South Africa


• Spain


• Sweden


• Switzerland


• Taiwan


• Tunisia


• Turkey


• United Kingdom


• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.